Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury during Liver Transplantation

Revive Therapeutics Ltd. announced that it has filed an application with the US FDA to receive Orphan Drug Designation for Bucillamine for the prevention of ischemia–reperfusion injury during liver transplantation.